Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Pharmacoeconomics|November 1, 2017
Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology AppraisalNasuh C Büyükkaramikli, Saskia de Groot, Debra Fayter, et al.
BMC Medicine|October 25, 2017
Faecal immunochemical tests (FIT) can help to rule out colorectal cancer in patients presenting in primary care with lower abdominal symptoms: a systematic review conducted to inform new NICE DG30 diagnostic guidanceMarie Westwood, Shona Lang, Nigel Armstrong, et al.
Pharmacoeconomics|November 28, 2017
Trifluridine-Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology AppraisalBram L T Ramaekers, Robert Wolff, Anoukh van Giessen, et al.
Pharmacoeconomics|October 27, 2022
Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology AppraisalBen Wijnen, Willem Witlox, Robert Wolff, et al.
Pharmacoeconomics|June 10, 2020
Cannabidiol for Adjuvant Treatment of Seizures Associated with Lennox-Gastaut Syndrome and Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology AppraisalBen Wijnen, Nigel Armstrong, Bram Ramaekers, et al.
Pharmacoeconomics|November 15, 2018
Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology AppraisalBram L T Ramaekers, Rob Riemsma, Sabine Grimm, et al.
Pharmacoeconomics|December 15, 2018
Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology AppraisalFrederick W Thielen, Nasuh C Büyükkaramikli, Rob Riemsma, et al.
Pharmacoeconomics|October 28, 2016
A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering TherapiesChing-Yun Wei, Ruben G W Quek, Guillermo Villa, et al.
Pharmacoeconomics|March 22, 2019
Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology AppraisalSabine E Grimm, Debra Fayter, Bram L T Ramaekers, et al.
Pharmacoeconomics|October 19, 2021
Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology AppraisalSabine E Grimm, Willem Witlox, Robert Wolff, et al.
Pageof 6